Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BPX-601 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BPX-601 monotherapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BPX-601 | GENETIC | Administered per protocol |
Key Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of hormone-refractory adenocarcinoma of the prostate without pure small cell carcinoma 2. Metastatic, Castration-Resistant Prostate Cancer (mCRPC) with PSA value at screening ≥4 ng/mL that has progressed within 6 months ...
Top 20 of 53 competitors
BPX-601 is an investigational gene therapy being studied for the treatment of prostate cancer that has returned, is resistant to treatment, and has spread. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
BPX-601 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol REGN. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of this investigational therapy.
BPX-601 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and effectiveness in patients with prostate cancer.
BPX-601 is being studied in a Phase 1 clinical trial with the identifier NCT07543055. This trial is recruiting adult male participants with prostate cancer that has returned, is resistant to treatment, and has spread. The study is being conducted in the United States and aims to enroll 36 participants.
Yes, BPX-601 is a CAR T-cell therapy, a type of gene therapy. It is being investigated in a Phase 1 study for the treatment of prostate cancer. The trial is uncontrolled, meaning there is no comparison group, and it is not randomized or double-blinded.